Investors diligence whether a team can execute its clinical plan within the capital it is raising. Strong science gets a biotech into the room. A credible operational plan, with realistic timelines, a complete budget, experienced leadership and a sound vendor strategy, is often what keeps it there.
What do investors ask about clinical operations?
Is the timeline realistic? Which assumptions about site startup and enrollment rate drive it, and where did they come from?
Is the budget complete? Does it include pass-through costs, drug supply, regulatory work and contingency, or only CRO fees?
Who will run the study? What clinical execution experience does the team have, and how will gaps be covered?
What is the vendor strategy? Has a CRO been selected, why, and on what terms? How dependent is the company on a single vendor?
Is the regulatory path clear? What has the agency said, and how has the plan responded?
What could go wrong? Which risks matter most, and what is the mitigation?
What does the milestone deliver? Which readout, when, and what decision will it enable?
What red flags do investors notice?
Timelines that assume everything goes right. Budgets with no contingency. A leadership team with deep science and no one who has run a trial. A CRO chosen by convenience rather than fit. Endpoints that are vague about what success looks like. And the most serious one: a plan whose key readout lands after the money runs out.
How should a biotech prepare?
An operational plan summary. The critical path to the next value-creating readout, the assumptions behind it and the top five risks with mitigations.
A driver-based budget. Built from sites, participants, visits and vendors, with contingency shown explicitly.
Evidence. Feasibility data, a comparison of CRO proposals, regulatory meeting minutes.
A team story. Who leads development and operations today, and how gaps are covered, whether through hiring, interim or fractional leadership.
A downside scenario. What happens to timeline and cash if enrollment runs 30 percent slower than planned.
Why does this help beyond fundraising?
The same discipline that satisfies investors improves execution. A team that has examined its assumptions, built a realistic budget and planned for the downside makes better decisions once the study starts. It also builds credibility for the next financing, when investors compare what was promised with what was delivered.
How candid should you be about risk?
Very. Experienced investors know clinical development is uncertain. What erodes confidence is not the existence of risk but a team that hasn't seen it. A clear-eyed risk register with credible mitigation is more persuasive than an optimistic plan that unravels at the first diligence question.
What do investors notice that management teams miss?
The gap between the science narrative and the operational one. Pitch decks often describe a study in a single line with a readout date. Investors who have seen many programs know that date sits on top of dozens of assumptions. Showing that you know them too is a quiet but powerful signal of execution maturity.
Building the operating leadership investors expect to see? Explore ABRA's Executive Leadership support.
